Novavax (NASDAQ:NVAX) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.24, RTT News reports. The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $4.40 million. During the same quarter in the previous year, the company posted ($2.40) EPS.
NVAX stock traded up $0.09 during trading hours on Friday, reaching $4.59. The stock had a trading volume of 858,200 shares, compared to its average volume of 807,410. Novavax has a fifty-two week low of $4.01 and a fifty-two week high of $51.60. The stock has a market capitalization of $106.69 million, a PE ratio of -0.46 and a beta of 1.90. The stock has a 50-day simple moving average of $4.91 and a 200 day simple moving average of $4.94.
Several research analysts recently commented on NVAX shares. Citigroup reduced their target price on shares of Novavax from $19.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, September 24th. Zacks Investment Research cut shares of Novavax from a “hold” rating to a “sell” rating in a report on Friday, October 25th. HC Wainwright increased their target price on shares of Novavax from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Oppenheimer reduced their target price on shares of Novavax from $25.00 to $13.00 and set an “outperform” rating for the company in a report on Tuesday, September 10th. Finally, LADENBURG THALM/SH SH restated a “buy” rating and set a $27.50 target price on shares of Novavax in a report on Friday. Three research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $31.15.
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Featured Story: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.